These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36572182)

  • 1. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
    Kritikos V; Harvey ES; Stevens S; Katelaris CH; Langton D; Rimmer J; Farah CS; Gillman A; Hew M; Radhakrishna N; Thomas D; Gibson PG;
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):885-895.e13. PubMed ID: 36572182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
    Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.
    Liu MC; Bagnasco D; Matucci A; Pilette C; Price RG; Maxwell AC; Alfonso-Cristancho R; Jakes RW; Lee JK; Howarth P
    J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3650-3661.e3. PubMed ID: 37507070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
    Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
    World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
    Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
    Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
    Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study].
    Bulut İ; Yegin Katran Z; Yavuz D; Yıldız AB; Yakut T; Örçen C; Mersin SS
    Tuberk Toraks; 2023 Jun; 71(2):148-155. PubMed ID: 37345397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
    Fyles F; Nuttall A; Joplin H; Burhan H
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
    J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.